These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37397721)

  • 1. Is sub-national healthcare social protection sufficient for protecting rare disease patients? the case of China.
    Xu J; Yu M; Zhang Z; Gong S; Li B
    Front Public Health; 2023; 11():1198368. PubMed ID: 37397721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of affordability differences for rare diseases in China: a comparison across disease types and regions.
    Chen Y; Chen X; Deng Y; Ding J
    Int J Equity Health; 2024 Mar; 23(1):64. PubMed ID: 38504266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health service security of patients with 8 certain rare diseases: evidence from China's national system for health service utilization of patients with healthcare insurance.
    Min R; Zhang X; Fang P; Wang B; Wang H
    Orphanet J Rare Dis; 2019 Aug; 14(1):204. PubMed ID: 31429789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China.
    Li X; Liu M; Lin J; Li B; Zhang X; Zhang S; Lu Z; Zhang J; Zhou J; Ou L
    Orphanet J Rare Dis; 2021 Jul; 16(1):327. PubMed ID: 34294091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the performance of social health insurance system through increasing outpatient expenditure reimbursement ratio: a quasi-experimental evaluation study from rural China.
    Miao Y; Gu J; Zhang L; He R; Sandeep S; Wu J
    Int J Equity Health; 2018 Jun; 17(1):89. PubMed ID: 29940956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New cooperative medical scheme decreased financial burden but expanded the gap of income-related inequity: evidence from three provinces in rural China.
    Ma J; Xu J; Zhang Z; Wang J
    Int J Equity Health; 2016 May; 15():72. PubMed ID: 27142618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.
    Czech M; Baran-Kooiker A; Atikeler K; Demirtshyan M; Gaitova K; Holownia-Voloskova M; Turcu-Stiolica A; Kooiker C; Piniazhko O; Konstandyan N; Zalis'ka O; Sykut-Cegielska J
    Front Public Health; 2019; 7():416. PubMed ID: 32117845
    [No Abstract]   [Full Text] [Related]  

  • 9. Multi-source financing for tuberculosis treatment in China: key issues and challenges.
    Long Q; Jiang WX; Zhang H; Cheng J; Tang SL; Wang WB
    Infect Dis Poverty; 2021 Mar; 10(1):17. PubMed ID: 33750460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical policies: effects of financial incentives for prescribers.
    Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constructing a value-based healthcare system for hypertensive patients through changing payment mode: evidence from a comparative study in rural China.
    Miao Y; Yuan X; Gu J; Zhang L; He R; Sandeep S; Wu J
    J Med Econ; 2019 Mar; 22(3):245-251. PubMed ID: 30547700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The challenge of healthcare big data to China's commercial health insurance industry: evaluation and recommendations.
    Wu J; Qiao J; Nicholas S; Liu Y; Maitland E
    BMC Health Serv Res; 2022 Sep; 22(1):1189. PubMed ID: 36138390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between an increased reimbursement cap for chronic disease coverage and healthcare utilization in China: an interrupted time series study.
    Shen M; He W; Yeoh EK; Wu Y
    Health Policy Plan; 2020 Oct; 35(8):1029-1038. PubMed ID: 32869090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [FINANCING OF MEDICINES FOR TREATMENT OF RARE DISEASES OF THE NERVOUS SYSTEM. ORPHAN DRUGS IN RARE NEUROLOGICAL DISEASES].
    Szegedi Márta ; Kosztolányi G; Boncz I; Molnár MJ
    Ideggyogy Sz; 2016 Jan; 69(1-2):37-45. PubMed ID: 26987239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical crowdfunding in a healthcare system with universal coverage: an exploratory study.
    Lublóy Á
    BMC Public Health; 2020 Nov; 20(1):1672. PubMed ID: 33167927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants and Equity Evaluation for Health Expenditure Among Patients with Rare Diseases in China.
    Xin XX; Zhao L; Guan XD; Shi LW
    Chin Med J (Engl); 2016 Jun; 129(12):1387-93. PubMed ID: 27270531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The needs of patients with rare disease in Serbia. Why do we need National Strategy for rare disease?
    Joldic M; Todorovic J; Terzic-Supic Z
    Health Soc Care Community; 2019 Sep; 27(5):e861-e870. PubMed ID: 31314147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis.
    Yang J; Atkins KE; Feng L; Pang M; Zheng Y; Liu X; Cowling BJ; Yu H
    Vaccine; 2016 Nov; 34(47):5724-5735. PubMed ID: 27745951
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.